First-in-Human Data from Ph 1 Trial of GTA182 in MTAP-Deleted Advanced NSCLC presented
“We are pleased to share the first clinical data for GTA182, which demonstrate strong target engagement, early tumor responses, and encouraging signs of intracranial activity in patients with MTAP-deleted advanced solid tumors,” said Mingxi Li, Ph.D., Chief Executive Officer of Apeiron Therapeutics. “These results highlight GTA182’s differentiated profile as a brain-penetrant, MTA-cooperative PRMT5 inhibitor designed specifically for MTAP-deleted tumors. The emerging safety, PK/PD, and antitumor activity data support continued dose exploration and advancement toward expansion cohorts.”
Share:
More News
“The initial efficacy data from the Part C studies are consistent with the encouraging efficacy signals we previously reported for Parts A and B of THIO-101, including an 88% disease control rate in third-line NSCLC patients. This measure of efficacy is close to triple the reported outcome for standard-of-care chemotherapy
“Patients with non-muscle invasive bladder cancer continue to face a significant risk of disease recurrence despite available treatment options,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy tumor cells while generating an anti-tumor immune response. FDA clearance of
“Whitehawk has established strong expertise in ADC technology and oncology drug development,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This collaboration further expands the application of Biocytogen’s fully human bispecific antibodies in ADC development. We look forward to supporting the efficient advancement of multiple programs by contributing high-quality
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The AZUR-1 results support the potential for dostarlimab to transform treatment for dMMR/MSI-H locally advanced rectal cancer. For many patients today, rectal cancer treatment comes with the tolerability burden and lasting impacts from chemotherapy, radiation and surgery. These data